

Severity Predictors of COVID-19 in SARS-CoV-2 Variant, Delta and Omicron Period; Single Center Study

Fumihiro Ogawa, MD, PhD, Yasufumi Oi, MD, PhD, Hiroshi Honzawa, MD, Naho Misawa, MD, Tomoaki Takeda, MD, Yuusuke Kikuchi, MD, Ryosuke Fukui, MD, Katsushi Tanaka, MD, PhD, Daiki Kano, MD, Hideaki Kato, MD, PhD, Takeru Abe, MA, PhD, Ichiro Takeuchi, MD, PhD

Department of Emergency Medicine, Yokohama City University, School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan

Fumihiro Ogawa; fumihiro@yokohama-cu.ac.jp

Yasufumi Oi; yasu7azteca@ybb.ne.jp

Hiroshi Honzawa; doubleh@yokohama-cu.ac.jp

Naho Misawa; mon_naho_mla@yahoo.co.jp

Tomoaki Takeda; magical@yokohama-cu.ac.jp

Yushi Kikuchi; yushimail.k1213@gmail.com

Ryosuke Fukui; Ryosuke.29119921005@gmail.com

Katsushi Tanaka; t226043g@yokohama-cu.ac.jp

Daiki Kano; swazxde2000@gmail.com

Hideaki Kato; ekato@yokohama-cu.ac.jp

Takeru Abe; abet@yokohama-cu.ac.jp

Ichiro Takeuchi; itake@myad.jp

***Corresponding author:**

Fumihiro Ogawa, MD, PhD

Department of Emergency Medicine, Yokohama City University, School of Medicine

3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan

Phone: +81-45-787-2800 e-mail: fumihiro@yokohama-cu.ac.jp

Short Title:

Severity Predictors of COVID-19 in SARS-CoV-2 Variant

1 **Abstract**

2 **Background:** The outcomes of coronavirus disease 2019 (COVID-19) treatment have
3 improved due to vaccination and the establishment of better treatment regimens. However,
4 the emergence of variants of the severe acute respiratory syndrome coronavirus 2 (SARS-
5 CoV-2), which causes COVID-19, and the corresponding changes in the characteristics of the
6 disease present new challenges in patient management. This study aimed to analyze
7 predictors of COVID-19 severity caused by the delta and omicron variants of SARS-CoV-2.

8 **Methods:** We retrospectively analyzed the data of patients who were admitted for COVID-19
9 at Yokohama City University Hospital from August 2021 to March 2022.

10 **Results:** A total of 141 patients were included in this study. Of these, 91 had moderate
11 COVID-19, whereas 50 had severe COVID-19. There were significant differences in sex,
12 vaccination status, dyspnea, sore throat symptoms, and body mass index (BMI) ($p < 0.0001$, p
13 < 0.001 , $p < 0.001$, $p = 0.02$, $p < 0.0001$, respectively) between the moderate and severe
14 COVID-19 groups. Regarding comorbidities, smoking habit and renal dysfunction were
15 significantly different between the two groups ($p = 0.007$ and $p = 0.01$, respectively). Regarding
16 laboratory data, only LDH level on the first day of hospitalization was significantly different
17 between the two groups ($p < 0.001$). Multiple logistic regression analysis revealed that time
18 from the onset of COVID-19 to hospitalization, BMI, smoking habit, and LDH level were
19 significantly different between the two groups ($p < 0.03$, $p = 0.039$, $p = 0.008$, $p < 0.001$,
20 respectively). The cut-off value for the time from onset of COVID-19 to hospitalization was
21 four days (sensitivity, 0.73; specificity, 0.70).

22 **Conclusions:** Time from the onset of COVID-19 to hospitalization is the most important
23 factor in the prevention of the aggravation of COVID-19 caused by the delta and omicron
24 SARS-CoV-2 variants. Appropriate medical management within four days after the onset of

25 COVID-19 is essential for preventing the progression of COVID-19, especially in patients

26 with smoking habits.

27 **Keywords:** COVID-19, Variant, Delta, Omicron, Severity, Predictor

28 **Introduction**

29 The coronavirus disease 2019 (COVID-19) pandemic has caused a significant
30 increase in hospitalizations for pneumonia with multiorgan disease. COVID-19 is caused by
31 the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Vaccines and
32 treatment methods against SARS-CoV-2 are increasingly being developed worldwide.
33 Although the number of patients with COVID-19 is still high, these measures have led to the
34 reduction of disease severity and improvement of prognosis after the onset of symptoms.
35 However, despite tremendous efforts by scientists, researchers, and health practitioners to
36 combat the COVID-19 pandemic, the emergence of new variants of SARS-CoV-2 present
37 new challenges in patient management. As the development of vaccines and treatments
38 progresses and patient outcomes improve, SARS-CoV-2 repeatedly mutates and tries to
39 survive these improved therapies. The World Health Organization and Centers for Disease
40 Control and Prevention have identified the alpha, beta, gamma, delta, epsilon, eta, Iota, kappa,
41 mu, zeta, and omicron variants of SARS-CoV-2 [1, 2]. The recently identified delta and
42 omicron variants are both highly infectious and are different from the previous strains in
43 terms of infectivity, severity, and clinical symptoms. Thus, retrospective analysis of the
44 characteristics and aggravation markers of patients newly infected with the delta and omicron
45 variants of SARS-CoV-2 is essential and will lay the groundwork for the management of the
46 emergence of new mutant strains of SARS-CoV-2. Therefore, this study aimed to analyze
47 and describe the characteristics, clinical features, and outcomes of COVID-19 caused by the
48 delta and omicron variants of SARS-CoV-2 according to disease severity.

49

50

51

52

53 **Patients and methods**

54 This was a retrospective study conducted using the data of patients with COVID-19
55 (except for outpatients with mild COVID-19) who underwent standard treatment, including
56 intensive care, at Yokohama City University Hospital from June 2021 to March 2022. The
57 clinical and biological features of the patients were analyzed. During the observation period,
58 June 2021 to December 2021 and January 2022 to March 2022 were marked by a surge in the
59 number of infections caused by the delta and omicron variants of SARS-CoV-2, respectively.
60 Thus, we defined June 2021 to December 2021 as the ‘delta period’ and January 2022 to
61 March 2022 as the ‘omicron period.’ If a patient with mild COVID-19 had a severe risk
62 factor, such as old age, chronic kidney disease that requires hemodialysis, or severe
63 immunosuppression, we judged the patient’s condition and COVID-19 severity and decided
64 on hospitalization. The characteristics, risk factors, morbidity, and mortality outcomes of the
65 patients were analyzed as well. Information on comorbidities were obtained for each patient,
66 and outcome data were obtained during follow-up in our hospital.

67 This study was approved by the Ethics Committee of the Yokohama City University
68 School of Medicine. Written informed consent was obtained from each patient or their family
69 members before treatment.

70 **Classification of coronavirus disease severity**

71 Disease severity was categorized into the mild-moderate stage (moderate group) and
72 the severe-critical stage (severe group) based on previously published guidelines on the
73 diagnosis and treatment of COVID-19 [3]. Mild cases were defined as patients with no
74 symptoms, no need for oxygen, and no sign of pneumonia on computed tomography (CT)
75 scans. Moderate cases were defined as patients with mild respiratory symptoms, radiological
76 evidence of pneumonia, and oxygen saturation (SpO₂) >93% and <96%. Severe cases were

77 defined as patients with $SpO_2 \leq 94\%$ and requiring oxygen support. Critical cases were
78 defined as patients that required heart–lung machine or extracorporeal membrane
79 oxygenation (ECMO) support for acute respiratory distress syndrome (ARDS). Severe and
80 critical cases were combined into the same group in this study. We did not consider CT score
81 [4, 5] in the classification of COVID-19 severity.

82 **Sample collection**

83 The blood samples of the patients were collected at admission depending on the
84 clinical conditions of the patients with severe COVID-19 who needed oxygen and those in
85 critical conditions who needed intubation management. Table 1 shows the severity
86 classification and treatment strategies for the patients with critical COVID-19. On admission
87 to our hospital, COVID-19 was diagnosed using a positive reverse transcriptase–polymerase
88 chain reaction (RT-PCR) assay for SARS-CoV-2. The RT-PCR assay was performed using
89 respiratory tract and laryngeal swab samples, which were sent to a designated diagnostic
90 laboratory. Standard procedures for sample collection were used to ensure that all the
91 samples were treated rapidly and equally.

92 **Data collection**

93 Patients were followed up until hospital discharge or death. The patient information collected
94 included demographic characteristics, pre-existing comorbidities on the date of
95 hospitalization, and laboratory test results. The laboratory tests included measurement of
96 several hemostatic biomarkers, such as white blood cell count (WBC) and D-dimer, C-
97 reactive protein (CRP), aspartate aminotransferase (AST), alanine aminotransferase (ALT),
98 lactate dehydrogenase (LDH), blood urea nitrogen (BUN), creatinine (Cre), total bilirubin
99 (T.bil), and interleukin-6 (IL-6) levels, which have been reported to be severity markers of
100 COVID-19. These biomarker levels measured from the day of admission to the day of
101 discharge depending on the patient’s condition.

102 We recorded the clinical interventions administered during the observation period,
103 including the use of antibiotics, antiviral agents, systemic corticosteroids, vasoactive
104 medications, venous thromboembolism prophylaxis, antiplatelet or anticoagulation treatment,
105 renal replacement therapy, high-flow oxygen therapy, and mechanical ventilation (invasive
106 and noninvasive).

107 **Statistical analysis**

108 Patients were divided into two groups for comparison: the moderate group and the
109 severe group. For each group, medians (interquartile ranges) and frequencies (%) were
110 reported for continuous and categorical variables, respectively. We used the Mann-Whitney
111 U test for analysis of continuous variables and Fisher's exact test for the evaluation of
112 categorical variables. Patient characteristics, time from the onset of COVID-19 or acquisition
113 of a positive PCR result to hospitalization, results of standard blood tests, and physical
114 condition were analyzed. In addition, repeated measures analyses of variance was used to
115 evaluate group and time differences, as well as their interactions, for WBC and D-dimer,
116 CRP, AST, ALT, LDH, BUN, Cre, T.bil, and IL-6 levels. We utilized a multivariable logistic
117 regression model to identify the relationship between COVID-19 severity and patient
118 characteristics, including primary symptoms, comorbidities, and laboratory data. In addition,
119 to determine an optimal cut-off value of the interval between onset and admission for
120 different periods of COVID-19 variants, the receiver operating curve, ROC, analysis was
121 performed. The area under the curve, AUC, sensitivity, specificity, and their 95% confidence
122 interval were calculated. Two-sided P values < 0.05 were considered statistically significant.
123 All statistics analyses were conducted using JMP Pro Version 15 (SAS Institute Inc., Cary,
124 NC, USA) and IBM SPSS Statistics for Windows, Version 25.0 (Armonk, NY: IBM Corp).

125

126

127 **Results**

128 We analyzed 141 patients with COVID-19 (median age, 59.6 [IQR, 56–62] years)
129 who required hospitalization and were admitted to our hospital during the study period.
130 Baseline demographic characteristics, sex, age, time from onset of COVID-19 to
131 hospitalization, primary symptoms, physical characteristics, smoking habits, vaccination
132 status, and comorbidities of the patients are reported in Table 2. Characteristics of patients
133 admitted during the delta and omicron periods are summarized in Supplemental Table 1. The
134 data showed significant differences in patients' age, time from onset to hospitalization,
135 dyspnea as a primary symptom, weight, body mass index (BMI), cardiac disease, renal
136 dysfunction, continuous hemodialysis, and hypertension as comorbidities between the two
137 periods ($p < 0.001$, $p < 0.0001$, $p = 0.03$, $p = 0.027$, $p = 0.024$, $p < 0.0001$, $p = 0.0003$, $p = 0.01$, and
138 $p = 0.0027$, respectively). The major difference between the delta and omicron periods was
139 believed to be attributable the effect of vaccination on the public.

140 **Classification of coronavirus disease severity**

141 Of the 141 patients analyzed in this study, 91 had moderate COVID-19 and did not
142 need intensive care, whereas 50 had severe COVID-19 and needed mechanical ventilation.
143 The characteristics, primary symptoms, comorbidities, and primary laboratory data of the
144 patients classified according to COVID-19 severity are shown in Table 3. There was no
145 significant difference in age between the moderate group (59 ± 17.5 years; range, 19-93 years)
146 and the severe group (57 ± 13.3 years; range, 30-93 years) ($p = 0.31$). Male patients were more
147 likely to progress to severe COVID-19 than were female patients ($p = 0.0006$). Time from the
148 onset of COVID-19 symptoms to the day of hospitalization was significantly longer in the
149 severe group than in the moderate group (moderate group: 3 ± 3.6 days; range, 0-13 days vs.
150 severe group: 8 ± 4.2 days; range, 0-22 days) ($p < 0.0001$). However, there was no significant

151 difference between the two groups in terms of the time from the acquisition of a positive PCR
152 test result to hospitalization (moderate group: 1 ± 2.3 days; range, 0-13 days vs. severe group:
153 2 ± 2.3 days, range, 0-10 days) ($p=0.06$). Regarding primary symptoms, there was a significant
154 difference in the frequency of dyspnea between the two groups ($p<0.0001$). Regarding
155 physical features, patients in the severe group generally had a greater body weight (59.9 ± 16.0
156 kg vs. 74.1 ± 16.5 kg) and higher BMI (22.8 ± 10.8 vs. 26.3 ± 8.0) than those in the moderate
157 group ($p<0.0001$ and $p=0.0001$, respectively). Smoking habit was significantly different
158 between the two groups ($p=0.007$). No significant frequency of any comorbidity was
159 observed in the severe group. However, renal disease was significantly more frequent in the
160 moderate group than in the severe group ($p=0.016$).

161 Regarding laboratory data on the day of admission, there were significant differences
162 in AST (34.0 ± 40.2 IU/l vs. 50.5 ± 46.9 IU/l), ALT (21.0 ± 30.0 IU/l vs. 50.5 ± 41.3 IU/l), and
163 LDH (300.0 ± 136.7 IU/l vs. 499.5 ± 192.1 IU/l) levels between the severe and moderate groups
164 ($p<0.0001$, $p<0.0001$, and $p<0.0001$, respectively). However, differences in IL-6 (52.3 ± 121.7
165 pg/ml vs. 31.3 ± 75.3 pg/ml), CRP (5.7 ± 6.8 mg/dl vs. 6.4 ± 7.5 mg/dl), and D-dimer (1.2 ± 13.2
166 $\mu\text{g/ml}$ vs. 1.1 ± 9.6 $\mu\text{g/ml}$) levels between the two groups were not statistically significant
167 ($p=0.16$, $p=0.2$, and $p=0.85$, respectively).

168 Table 4 shows therapeutic strategies implemented for the treatment of the cases of
169 moderate and severe COVID-19. There was a significant difference between the moderate
170 and severe groups in terms of oxygen demand and intensive care beyond ventilator
171 management. In addition, there was a significant difference between the two groups in terms
172 of the characteristics of each treatment.

173 The above-mentioned results regarding the characteristics and clinical features of the
174 moderate and severe groups, as well as the clinical characteristics of the patients admitted
175 during the delta and omicron periods stratified according to disease severity, are outlined in

176 Supplemental Table 2. The greatest difference between the delta and omicron periods was the
177 difference in the spread of vaccination. Thus, there were some significant differences in
178 vaccination-associated factors between the two periods.

179 **Multivariable logistic regression analysis**

180 Multivariable logistic regression analysis was performed to identify the relationship
181 between COVID-19 severity and patient characteristics, including primary symptoms,
182 comorbidities, and laboratory data. The results showed that time from the onset of COVID-19
183 to hospitalization, BMI, smoking habits, and LDH level were significantly associated with
184 the COVID-19 severity (OR=1.16, p=0.026; OR=1.10, p=0.039; OR=3.70, p=0.008; and
185 OR=1.01, p< 0.001, respectively) (Table 5). The ROC curve (Fig. 1) showed that the time
186 from the onset of COVID-19 to hospitalization is an important factor associated with the
187 COVID-19 severity (AUC, 0.77 [95%CI, 0.69-0.84]; sensitivity, 0.73 [95%CI, 0.59-0.84];
188 specificity, 0.70 [0.59-0.79]). The ROC also showed that the cut-off value for the time from
189 the onset of COVID-19 to hospitalization was four days.

190 Discussion

191 In this single-center retrospective study, we analyzed the characteristics, clinical
192 features, and outcomes of COVID-19 caused by the delta and omicron variants of SARS-
193 CoV-2 according to disease severity. The authors of previous reports [6, 7] have suggested
194 that the hyperactivation of the inflammatory cascade, leading to a cytokine storm, is a critical
195 biological response in patients with severe COVID-19. In addition, D-dimer, LDH, and CRP
196 levels are reported to be potential biomarkers for COVID-19 severity [6, 7]. Significantly
197 elevated levels of inflammatory cytokines TNF- α , IL-1, IL-6, and IL-10 have been
198 documented in cases of severe COVID-19 compared to cases of non-severe disease [8-12]. In
199 the present study, we did not focus on the levels of inflammatory cytokines for the
200 classification of COVID-19 severity. The present results showed that LDH, which is reported
201 to be a predictive biomarker for the aggravation of COVID-19 caused by the original variant
202 of SARS-CoV-2, is involved in the aggravation of COVID-19 caused by the delta and
203 omicron variants. Abnormalities in the levels of markers of cellular injury, particularly
204 elevated LDH level, have been linked to greater disease severity [13, 14]. Data from recent
205 studies suggest that LDH may be related to respiratory function and could be an important
206 predictor of respiratory failure in patients with COVID-19 [15]. On the contrary, the present
207 results indicated that IL-6, which has received considerable attention as a biomarker of the
208 progression of COVID-19, is not a predictive factor for the aggravation of COVID-19. It has
209 been reported [16-18] that SARS-CoV-2 infection increases the level of the inflammatory
210 cytokine IL-6, which is believed to cause multiple organ damage. Therefore, administration
211 of an IL-6 inhibitor has been established as a therapeutic strategy for COVID-19. However,
212 as the IL-6 levels of the patients in the present study were not significantly high, even in the
213 severe group, it could be concluded that IL-6 inhibitors may not be effective against COVID-
214 19. The possible reasons for the lack of significant increase in IL-6 levels in the severe group

215 are as follows: 1) the delta and omicron variants of SARS-CoV-2 could be less toxic than the
216 original variant due to mutations, 2) SARS-CoV-2 may have mutated to induce inflammatory
217 cytokines other than IL-6, and 3) IL-6 may not completely respond to SARS-CoV-2 infection
218 due to the effect of vaccination. However, since vaccination was not yet widespread during
219 the delta period, its effect may not have been extensive. In addition, since IL-6 level was
220 measured on the first day of hospitalization in this study, it is unlikely that it was affected by
221 the therapeutic drug administered. Thus, although we considered that various factors may be
222 responsible for the lack of significant increase in IL-6 levels, the influence of the mutation of
223 SARS-CoV-2 may be large. Furthermore, the lack of a significant increase in CRP and D-
224 dimer levels was also considered to be due to the mutation of the virus.

225 It has been reported that cardiovascular disease, chronic renal disease, chronic lung
226 diseases, diabetes mellitus, hypertension, immunosuppression, obesity, malignant tumor, and
227 sickle cell disease are prognostic factors of COVID-19 severity [13, 19-22]. We investigated
228 these comorbidities in the present study and found that except for obesity, there were no
229 significant differences between the comorbidities of the patients in the moderate and severe
230 COVID-19 groups. However, significantly more patients with moderate COVID-19 had
231 chronic renal failure than those with severe COVID-19. The reason for this finding is that it
232 was difficult for patients to receive medical treatment in the outpatient dialysis clinic because
233 chronic renal failure is one of the risk factors for aggravation of COVID-19. Regarding
234 obesity, BMI >30, which is a proxy for obesity, was considered a strong predictor in a
235 previous report [22]. There was a significant difference in BMI between the moderate and
236 severe groups in the present study. During the delta period, patients with a high BMI
237 developed more severe COVID-19. In addition, it was extremely difficult to manage their
238 systemic conditions using mechanical ventilation, prone position therapy, and ECMO.
239 However, BMI was considered to be slightly associated with COVID-19 severity during the

240 omicron period. It has been suggested that the effect of the COVID-19 vaccine may
241 contribute to the prevention of aggravation in patients with a high BMI.

242 In this study, we analyzed diabetes mellitus and glycated hemoglobin level, which
243 have been reported to be linked to inflammation, hypercoagulation, and high mortality
244 (27.7%) [23], and found no significant differences between the moderate and severe groups.
245 Therefore, abnormal glucose tolerance was not a predictor of aggravation in this study.

246 Regarding the time from the onset of COVID-19 to hospitalization, most patients felt
247 some symptoms of COVID-19, such as fever, sore throat, and fatigue, and rested while
248 waiting for recovery of their physical condition. In such a scenario, the respiratory status of
249 the patient gradually worsens and the disease severity progresses. This is because after
250 SARS-CoV-2 infection is established, the patient's respiratory condition gradually
251 deteriorates and the patient is placed in a condition in which breathing is not difficult, even in
252 a hypoxic state. This condition is called 'happy hypoxia' and is considered to be a precursor
253 to the deterioration of respiratory function. This respiratory disorder caused by excessive
254 spontaneous breathing without ventilator management is called patient self-inflated lung
255 injury (P-SILI). This concept was previously described [24, 25] as a possible interplay
256 between ventilation, surfactant dysfunction, and atelectasis during spontaneous ventilation,
257 which leads to ventilation-induced lung injury. In clinical settings, intravenous injection of
258 small doses of endotoxin in humans has a strong effect on respiratory drive, independent of
259 fever or symptoms [26]. In addition, some patients without any pre-existing lung injury
260 develop lung injury associated with hyperventilation [27]. Thus, in some patients, lung injury
261 due to increased tidal volumes and ventilation may occur during spontaneous breathing,
262 initiated by a high respiratory drive, which, in turn, leads to the development of lesions that
263 appear similar to the ventilator-induced lung injury (VILI) observed in mechanically
264 ventilated subjects. In these patients, the large spontaneous tidal volumes may be viewed as

265 the cause of injury. Hence, any therapy that minimizes the generation of these large tidal
266 volumes should be viewed as a prophylactic therapy against the progression of lung injury.
267 Considering the above-mentioned concept, if a spontaneously breathing patient has a high
268 respiratory drive that leads to increased minute ventilation with high tidal volumes, the goal
269 of therapy must be to minimize P-SILI. If the patient engages in spontaneous breathing based
270 on self-judgement, some parameters, such as changes in spontaneous breathing styles,
271 tachypnea, changes in respiratory patterns, and oxygen demand, should be strictly managed,
272 and any changes should be addressed immediately. If the changes are not managed
273 immediately, the condition of the patient may become more severe. It is important to
274 ascertain whether a spontaneously breathing patient has a high respiratory drive and has
275 adopted a ventilatory pattern that will lead to subsequent lung injury. This concept is
276 important for the management of respiratory conditions under mechanical ventilation for
277 patients with severe COVID-19. The specific time from the onset of COVID-19 to
278 aggravation and how long the deterioration of respiratory status should be observed have not
279 been reported in any previous study. In the present study, the ROC showed that the optimal
280 time from the onset of COVID-19 to hospitalization is four days. In other words, it is highly
281 likely that COVID-19 will progress to severe if a patient's respiratory status is altered within
282 four days after the onset of COVID-19, even if the patient is receiving home care; thus,
283 immediate intervention is required. Proper intubation and a lung-protective ventilatory
284 strategy guided by the severity of lung injury, including elevations in dead space, may be the
285 easiest and most efficient way to achieve this goal. It is possible that by applying the same
286 principles, mechanical ventilation can be administered “prophylactically or early” to protect
287 the lung from P-SILI. As such, under defined conditions, mechanical ventilation, far from
288 being just supportive or even damaging, becomes a true preventive measure against the
289 progression of lung injury and perhaps ARDS. ECMO is another method that can be used to

290 prevent P-SILI. When ventilator management for patients with severe COVID-19 reaches its
291 limits, introduction of ECMO as a lung protection strategy may be expected for the
292 prevention of or recovery from ARDS. However, regarding the introduction of ECMO,
293 systemic management is necessary for weighing the possibility of the occurrence of serious
294 complications caused by ECMO.

295 This study had several limitations. First, this was a single-center retrospective study
296 performed in one of the leading hospitals in Japan, which has generally accepted and treated
297 a large number of severely ill COVID-19 patients since the outbreak of disease. Unlike some
298 countries, few hospitals in Japan collectively treat patients with COVID-19. Patients with
299 COVID-19 are dispersed to nearby hospitals for treatment; thus, a single hospital does not
300 treat many cases. Second, the moderate COVID-19 group in this study included elderly
301 patients who did not need hospitalization for COVID-19 but could not stay alone at home due
302 to lack of assistance from a caregiver. In addition, the moderate COVID-19 group included
303 patients with mild COVID-19 who had several comorbidities and risk factors or patients who
304 were hospitalized for the treatment of other illnesses but incidentally tested positive for
305 COVID-19 without showing any symptoms. Thus, there may be some bias in our clinical
306 data. Third, we did not establish exclusion criteria for this study and excluded patients
307 undergoing treatment for other diseases to ensure that only the severity predictors of COVID-
308 19 are considered. However, considering the spread of COVID-19 worldwide, the high
309 infectivity of SARS-CoV-2, and the severity of patient symptoms, we analyzed the severity
310 predictors without setting any exclusion criteria. Finally, this study focused on the
311 identification of predictors of the aggravation of COVID-19 using information available in
312 routine practice, results of measurable specimen testing, and data on patient management
313 based on standard of care. Combining these with the analysis of results of more advanced
314 examinations and diagnostic imaging tests should further narrow down the severity predictors.

315 However, although this may be possible for progressive research institutes, such as advanced
316 medical institutions and universities, we believed that it was more important to distinguish
317 COVID-19 severity in general medical institutions considering the spread of COVID-19
318 worldwide. The predictors identified this study, including the time from the onset of COVID-
319 19 to hospitalization, LDH level at hospitalization, BMI, and smoking habits, are easy to
320 understand and can be measured at any facility.

321

322 **Conclusion**

323 This study showed that the time from the onset of COVID-19 to hospitalization is the
324 most important factor in the prevention of the aggravation of COVID-19 caused by the delta
325 and omicron variants of SARS-CoV-2. To prevent the aggravation of COVID-19, it is
326 necessary to initiate appropriate medical management within four days after the onset of
327 COVID-19, especially in patients with smoking habits, high BMI, and elevated LDH levels.
328 These findings may facilitate preparations for the next wave of COVID-19 caused by other
329 possible variants of SARS-CoV-2.

330 **Acknowledgements**

331 We would like to thank our colleagues in Department of Emergency Medicine and
332 clinical nurses in the intensive care unit of Yokohama City University Hospital and
333 Yokohama City University Medical Center Hospital for their kind assistance. And, we would
334 like to thank Editage (www.editage.com) for English language editing.

335

336 **Declarations**

337 Ethical approval to report this case was obtained from Yokohama City University
338 Hospital (No.B200200048).

339

340 **Consent for publication**

341 Written consent was obtained from patients for the publication of this case report and
342 the relevant images. A copy of the written consent is available for review by the Editor-in-
343 Chief of PLOS One

344

345 **Availability of data and materials**

346 Data requests should be made to the corresponding authors.

347

348 **Informed Consent**

349 Written informed consent was obtained from the patients for their anonymized information to
350 be published in this article.

351

352 **Funding**

353 This study was not supported by any funding.

354

355 **Competing interests**

356 The authors declare that there are no conflicts of interest regarding the publication of this

357 paper.

358

359 **Authors' contributions**

360 FO prepared the manuscript and collected the references. IT coordinated the authors. FO, YO,

361 HH, NM, TT, YK, RF, KT, DK and HK provided clinical support. TA helped to draft the

362 manuscript. All authors have read and approved the final manuscript.

363 References

- 364 1. World Health Organization. Tracking SARS-CoV-2 Variants [cited 2022 Jul 21].
365 Available from: <https://www.who.int/activities/tracking-SARS-CoV-2-variants>
- 366 2. Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and
367 Definitions. 2022 Apr 26 [cited 2022 Jun 21]. Available from:
368 <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html>
- 369 3. Gandhi RT, Lynch JB, Del Rio C. Mild or moderate COVID-19. *N Engl J Med*.
370 2020;383: 1757-1766.
- 371 4. Yuyun X, Lexi Y, Haochu W, Zhenyu S, Xiangyang G. Early warning information
372 for severe and critical patients with COVID-19 Based on quantitative CT analysis of
373 lung segments. *Front Public Health*. 2021; 9: 596938.
- 374 5. Zhou S, Zhu T, Wang Y, Xia L. Imaging features and evolution on CT in 100
375 COVID-19 pneumonia patients in Wuhan, China. *Eur Radiol*. 2020;30: 5446-5454.
- 376 6. Ayanian S, Reyes J, Lynn L, Teufel K. The association between biomarkers and
377 clinical outcomes in novel coronavirus pneumonia in a US cohort. *Biomark Med*.
378 2020;14: 1091-1097.
- 379 7. Nakajima K, Abe T, Saji R, Ogawa F, Taniguchi H, Yamaguchi K, et al. Serum
380 cholinesterase associated with COVID-19 pneumonia severity and mortality. *J Infect*.
381 2021;82: 282-327.
- 382 8. Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, et al. [Analysis of clinical features of
383 29 patients with 2019 novel coronavirus pneumonia]. *Zhonghua Jie He He Hu Xi Za*
384 *Zhi*. 2020;43: E005.
- 385 9. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in
386 patients with COVID-19. *Lancet Haematol*. 2020;7: e438-e440.
- 387 10. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to
388 COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive*
389 *Care Med*. 2020;46: 846-848.
- 390 11. Wang W, Liu X, Wu S, Chen S, Li Y, Nong L, et al. Definition and risks of cytokine
391 release syndrome in 11 critically ill COVID-19 patients with pneumonia: Analysis of
392 disease characteristics. *J Infect Dis*. 2020;222:1444-1451.
- 393 12. Sugiyama M, Kinoshita N, Ide S, Nomoto H, Nakamoto T, Saito S, et al. Serum
394 CCL17 level becomes a predictive marker to distinguish between mild/moderate and
395 severe/critical disease in patients with COVID-19. *Gene*. 2021;766: 145145.
- 396 13. Cecconi M, Piovani D, Brunetta E, Aghemo A, Greco M, Ciccarelli M, et al. Early
397 predictors of clinical deterioration in a cohort of 239 patients hospitalized for
398 COVID-19 infection in Lombardy, Italy. *J Clin Med*. 2020;9: 1548
- 399 14. Li Q, Cao Y, Chen L, Wu D, Yu J, Wang H, et al. Hematological features of persons
400 with COVID-19. *Leukemia*. 2020;34: 2163-2172.
- 401 15. Poggiali E, Zaino D, Immovilli P, Rovero L, Losi G, Dacrema A, et al. Lactate
402 dehydrogenase and C-reactive protein as predictors of respiratory failure in COVID-
403 19 patients. *Clin Chim Acta*. 2020; 509:135-138.
- 404 16. Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for
405 coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? *J*
406 *Autoimmun*. 2020;111: 102452.
- 407 17. Tharmarajah E, Buazon A, Patel V, Hannah JR, Adas M, Allen VB, et al. IL-6
408 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression. *J*
409 *Infect*. 2021;82: 178-185.

- 410 18. Tasoudis PT, Arvaniti CK, Adamou AT, Belios I, Stone JH, Horick N, et al.
411 Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual
412 patient data meta-analysis from randomized controlled trials. *Eur J Intern Med.* 2022;
413 101: 41-48.
- 414 19. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for
415 mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort
416 study. *Lancet.* 2020;395: 1054-1062.
- 417 20. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients
418 infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395: 497-506.
- 419 21. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of
420 113 deceased patients with coronavirus disease 2019: Retrospective study. *BMJ.*
421 2020;368: m1091.
- 422 22. Centers for Disease Control and Prevention. People with certain medical conditions.
423 2022 May 2 [cited 2022 Jun 21]. Available from:
424 [https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html?%20CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fneed-extra-precautions%2Fgroups-at-higher-risk.%20html)
425 [medical-](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html?%20CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fneed-extra-precautions%2Fgroups-at-higher-risk.%20html)
426 [conditions.html?%20CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcorona-](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html?%20CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fneed-extra-precautions%2Fgroups-at-higher-risk.%20html)
427 [virus%%202F2019-ncov%2Fneed-extra-precautions%2Fgroups-at-higher-](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html?%20CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fneed-extra-precautions%2Fgroups-at-higher-risk.%20html)
428 [risk.%20html](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html?%20CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fneed-extra-precautions%2Fgroups-at-higher-risk.%20html).
- 429 23. Wang Z, Du Z, Zhu F. Glycosylated hemoglobin is associated with systemic
430 inflammation, hypercoagulability, and prognosis of COVID-19 patients. *Diabetes Res*
431 *Clin Pract.* 2020;164: 108214.
- 432 24. Yoshida T, Fujino Y, Amato MB, Kavanagh BP. Fifty years of research in ARDS.
433 Spontaneous breathing during mechanical ventilation. Risks, mechanisms, and
434 management. *Am J Respir Crit Care Med.* 2017;195: 985-992.
- 435 25. Albert RK. The role of ventilation-induced surfactant dysfunction and atelectasis in
436 causing acute respiratory distress syndrome. *Am J Respir Crit Care Med.* 2012;185:
437 702-708.
- 438 26. Preas HL, Jubran A, Vandivier RW, Reda D, Godin PJ, Banks SM, et al. Effect of
439 endotoxin on ventilation and breath variability: role of cyclooxygenase pathway. *Am*
440 *J Respir Crit Care Med.* 2001;164: 620-626.
- 441 27. Brun-Buisson CJ, Bonnet F, Bergeret S, Lemaire F, Rapin M. Recurrent high-
442 permeability pulmonary edema associated with diabetic ketoacidosis. *Crit Care Med.*
443 1985;13: 55-56

444 **Figure legends**

445 **Figure 1.** Receiver Operatorating Characteristic of the period from onset to hospitalization

446 related to severity of COVID-19 with area under the curve 0.77, sensitivity 0.73, specificity

447 0.70. From the ROC, the cut-off value of the period from onset of COVID-19 to

448 hospitalization was 4 days.

The period from onset to hospitalization

